Insmed Incorporated
HealthcareNASDAQ:INSM · NASDAQ Global Select
+$1.39 today
Vol 2.93M · Avg 3.15M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-172.8%
avg -135.0%
ROIC
-64.8%
avg -48.9%
ROA
-56.4%
avg -45.1%
Analysis
ROA is currently the strongest return metric at -56.4% versus its period average of -45.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
William H. Lewis | President, Chief Executive Officer & Chairman | $2.47M | — | 57 | $258,917.00 | 0.12% |
Martina Flammer | Chief Medical Officer | $1.22M | — | 62 | $60,486.00 | 0.03% |
Roger Adsett | Chief Operating Officer | $1.19M | — | 57 | $98,603.00 | 0.05% |
Michael Alexander Smith | Chief Legal Officer & Corporate Secretary | $1.14M | — | 48 | $39,454.00 | 0.02% |
Sara Bonstein | Chief Financial Officer | $1.12M | — | 45 | $69,082.00 | 0.03% |
S. Nicole Schaeffer | Chief People Strategy Officer | $660,810.00 | — | 58 | $41,754.00 | 0.02% |
Bryan Dunn | Vice President of Investor Relations | — | — | — | — | — |
Brian K. Kaspar | Chief Scientific Officer | — | — | 52 | — | — |
Christie Camelio | Chief Compliance Officer | — | — | — | — | — |
Claire Mulhearn | Vice President of Corporate Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
111
$77.52M
Net Sentiment
$77.52M
Net selling
Most Active
Lewis William
51 transactions
1–10 of 111
Analysis
Insiders reported 0 buys worth $0.00 and 111 sells worth $77.52M over the last 12 months. That adds up to net selling of $77.52M. Lewis William was the most active insider with 51 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A7 analysts |
| Revenue | N/A | N/A | N/A | N/A9 analysts |
| Net Income | N/A | N/A | N/A | N/A9 analysts |
| EBIT | N/A | N/A | N/A | N/A9 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Cardinal Health, Inc.
NYSE:CAH
$52.51B
Takeda Pharmaceutical Company Limited
NYSE:TAK
$50.48B
Humana Inc.
NYSE:HUM
$45.30B
Haleon plc
NYSE:HLN
$40.37B
Agilent Technologies, Inc.
NYSE:A
$36.53B
Alcon Inc.
NYSE:ALC
$32.53B
IQVIA Holdings Inc.
NYSE:IQV
$29.94B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$29.60B
BeOne Medicines Ltd.
NASDAQ:ONC
$28.29B
ResMed Inc.
NYSE:RMD
$28.10B
Who manages INSM?
Insmed Incorporated (INSM) lists 10 active executives. The top listed executive is Bryan Dunn, Vice President of Investor Relations.
Are INSM insiders buying or selling?
Recent insider activity shows net selling of $31.32M.
Explore More
Continue the stock analysis
Jump to another research area for this company.